RxDoctor Payments Data

John Beauman, MD

Family Medicine · Pueblo, CONPI 1497722441

Payments from drug & device makers

$8,220in general payments, 2019–2025

Across 525 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$888
  • Novo Nordisk$858
  • Johnson & Johnson$648
  • Pfizer$634
  • GSK$590
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$8,215100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,220 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$123,830
Medicare patients
294
Services billed
19,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$80,986
EliquisApixaban52$43,915
TrulicityDulaglutide25$39,828
JanuviaSitagliptin Phosphate19$25,274
JardianceEmpagliflozin15$25,268
XareltoRivaroxaban16$19,152
Repatha SureclickEvolocumab34$18,783
Synjardy XrEmpagliflozin/Metformin Hcl13$15,712
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$12,165
Breo ElliptaFluticasone/Vilanterol19$10,753
LinzessLinaclotide13$6,671
Aripiprazole18$6,250
Dexlansoprazole DrDexlansoprazole18$4,140
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,865
Rosuvastatin Calcium228$2,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$590$106,768153 claims
PfizerEliquis$634$43,91552 claims
Boehringer IngelheimJardiance, Synjardy Xr$121$40,98028 claims
Lilly USA, LLCTrulicity$140$39,82825 claims
MerckJanuvia, Janumet$256$27,50632 claims
Johnson & JohnsonXarelto$648$19,15216 claims
AbbVieLinzess$1,179$6,67113 claims
Sanofi-aventis U.S. LLCLantus$12$1,05113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →